In May, researchers reported something that would have sounded like science fiction a generation ago. In patients with high-risk melanoma, an experimental mRNA cancer therapy paired with an immunotherapy drug cut the risk of the cancer returning or killing them by nearly half. The same approach is now in late-stage trials for lung, kidney, and […]
In May, researchers reported something that would have sounded like science fiction a generation ago. In patients with high-risk melanoma, an experimental mRNA cancer therapy paired with an immunotherapy drug cut the risk of the cancer returning or killing them by nearly half. The same approach is now in late-stage trials for lung, kidney, and […]
<iframe src="https://statesidedaily.com/embed/cluster/cdfa4df4449044ca5e257ae37fa2611205bb8550" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="Kennedy’s HHS is sacrificing cancer cures for trial bar profits"></iframe>
